![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ENPP2 |
Gene summary for ENPP2 |
![]() |
Gene information | Species | Human | Gene symbol | ENPP2 | Gene ID | 5168 |
Gene name | ectonucleotide pyrophosphatase/phosphodiesterase 2 | |
Gene Alias | ATX | |
Cytomap | 8q24.12 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q13822 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5168 | ENPP2 | HCC1_Meng | Human | Liver | HCC | 5.20e-80 | 3.34e-01 | 0.0246 |
5168 | ENPP2 | HCC2_Meng | Human | Liver | HCC | 1.93e-02 | -1.54e-01 | 0.0107 |
5168 | ENPP2 | cirrhotic2 | Human | Liver | Cirrhotic | 1.75e-11 | 2.17e-01 | 0.0201 |
5168 | ENPP2 | HCC1 | Human | Liver | HCC | 3.65e-25 | 9.61e-01 | 0.5336 |
5168 | ENPP2 | HCC2 | Human | Liver | HCC | 3.55e-03 | 1.51e+00 | 0.5341 |
5168 | ENPP2 | S014 | Human | Liver | HCC | 2.03e-23 | 1.28e+00 | 0.2254 |
5168 | ENPP2 | S015 | Human | Liver | HCC | 8.19e-20 | 1.45e+00 | 0.2375 |
5168 | ENPP2 | S016 | Human | Liver | HCC | 2.87e-35 | 1.54e+00 | 0.2243 |
5168 | ENPP2 | S028 | Human | Liver | HCC | 6.78e-08 | 5.66e-01 | 0.2503 |
5168 | ENPP2 | S029 | Human | Liver | HCC | 7.60e-10 | 6.37e-01 | 0.2581 |
5168 | ENPP2 | HTA12-15-2 | Human | Pancreas | PDAC | 4.61e-06 | 5.22e-01 | 0.2315 |
5168 | ENPP2 | HTA12-25-1 | Human | Pancreas | PDAC | 3.47e-04 | 5.22e-01 | 0.313 |
5168 | ENPP2 | HTA12-26-1 | Human | Pancreas | PDAC | 3.84e-09 | 4.77e-01 | 0.3728 |
5168 | ENPP2 | HTA12-29-1 | Human | Pancreas | PDAC | 9.76e-28 | 6.54e-01 | 0.3722 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002260412 | Liver | Cirrhotic | regulation of cell morphogenesis | 127/4634 | 309/18723 | 1.45e-10 | 7.44e-09 | 127 |
GO:004424212 | Liver | Cirrhotic | cellular lipid catabolic process | 82/4634 | 214/18723 | 6.91e-06 | 1.08e-04 | 82 |
GO:001604212 | Liver | Cirrhotic | lipid catabolic process | 112/4634 | 320/18723 | 2.31e-05 | 3.03e-04 | 112 |
GO:009758111 | Liver | Cirrhotic | lamellipodium organization | 40/4634 | 90/18723 | 3.48e-05 | 4.26e-04 | 40 |
GO:190274511 | Liver | Cirrhotic | positive regulation of lamellipodium organization | 19/4634 | 37/18723 | 4.39e-04 | 3.57e-03 | 19 |
GO:190274311 | Liver | Cirrhotic | regulation of lamellipodium organization | 25/4634 | 54/18723 | 4.63e-04 | 3.75e-03 | 25 |
GO:0006643 | Liver | Cirrhotic | membrane lipid metabolic process | 69/4634 | 203/18723 | 1.89e-03 | 1.19e-02 | 69 |
GO:000166712 | Liver | Cirrhotic | ameboidal-type cell migration | 145/4634 | 475/18723 | 2.23e-03 | 1.36e-02 | 145 |
GO:00106327 | Liver | Cirrhotic | regulation of epithelial cell migration | 93/4634 | 292/18723 | 3.46e-03 | 1.92e-02 | 93 |
GO:00106317 | Liver | Cirrhotic | epithelial cell migration | 110/4634 | 357/18723 | 5.14e-03 | 2.65e-02 | 110 |
GO:00901327 | Liver | Cirrhotic | epithelium migration | 110/4634 | 360/18723 | 6.79e-03 | 3.35e-02 | 110 |
GO:00901307 | Liver | Cirrhotic | tissue migration | 111/4634 | 365/18723 | 7.66e-03 | 3.61e-02 | 111 |
GO:00464341 | Liver | Cirrhotic | organophosphate catabolic process | 52/4634 | 155/18723 | 8.42e-03 | 3.91e-02 | 52 |
GO:00106346 | Liver | Cirrhotic | positive regulation of epithelial cell migration | 58/4634 | 176/18723 | 8.54e-03 | 3.96e-02 | 58 |
GO:002260422 | Liver | HCC | regulation of cell morphogenesis | 188/7958 | 309/18723 | 4.84e-11 | 1.82e-09 | 188 |
GO:004424222 | Liver | HCC | cellular lipid catabolic process | 134/7958 | 214/18723 | 2.07e-09 | 5.79e-08 | 134 |
GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
GO:0090305 | Liver | HCC | nucleic acid phosphodiester bond hydrolysis | 152/7958 | 261/18723 | 1.90e-07 | 3.46e-06 | 152 |
GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
GO:003134611 | Liver | HCC | positive regulation of cell projection organization | 193/7958 | 353/18723 | 2.28e-06 | 3.08e-05 | 193 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ENPP2 | SNV | Missense_Mutation | novel | c.579N>T | p.Arg193Ser | p.R193S | Q13822 | protein_coding | tolerated(0.08) | probably_damaging(0.99) | TCGA-44-5644-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ENPP2 | SNV | Missense_Mutation | c.887N>A | p.Pro296Gln | p.P296Q | Q13822 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-44-7660-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Vaccine | recprame+as15 | PD | |
ENPP2 | SNV | Missense_Mutation | novel | c.590N>T | p.Thr197Ile | p.T197I | Q13822 | protein_coding | tolerated(0.2) | probably_damaging(0.999) | TCGA-44-7662-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ENPP2 | SNV | Missense_Mutation | c.2605N>A | p.Glu869Lys | p.E869K | Q13822 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-49-6761-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ENPP2 | SNV | Missense_Mutation | novel | c.867N>G | p.Ile289Met | p.I289M | Q13822 | protein_coding | tolerated(0.19) | benign(0.131) | TCGA-49-AAR4-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxol | PD |
ENPP2 | SNV | Missense_Mutation | c.1529C>T | p.Pro510Leu | p.P510L | Q13822 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-50-5045-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ENPP2 | SNV | Missense_Mutation | c.883N>A | p.Leu295Met | p.L295M | Q13822 | protein_coding | deleterious(0.04) | probably_damaging(0.99) | TCGA-55-8302-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ENPP2 | SNV | Missense_Mutation | c.1805G>C | p.Arg602Thr | p.R602T | Q13822 | protein_coding | tolerated(0.35) | benign(0.117) | TCGA-55-8507-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ENPP2 | SNV | Missense_Mutation | novel | c.968N>A | p.Pro323His | p.P323H | Q13822 | protein_coding | deleterious(0) | benign(0.296) | TCGA-64-5781-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
ENPP2 | SNV | Missense_Mutation | novel | c.385N>T | p.Asp129Tyr | p.D129Y | Q13822 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-86-8279-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5168 | ENPP2 | ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | inhibitor | 315661229 | ||
5168 | ENPP2 | ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | NSC-12188 | CHEMBL1089321 | 20349977 | |
5168 | ENPP2 | ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | (S)-CARBA CYCLIC-PHOSPHATIDIC ACID | CHEMBL1630084 | 21051230 | |
5168 | ENPP2 | ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | NSC-1741 | CHEMBL483302 | 20349977 | |
5168 | ENPP2 | ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | inhibitor | 354702264 | ||
5168 | ENPP2 | ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | inhibitor | 315661228 | ||
5168 | ENPP2 | ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | NSC-34937 | CHEMBL1092743 | 20349977 | |
5168 | ENPP2 | ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | NSC-1698 | CHEMBL1093490 | 20349977 | |
5168 | ENPP2 | ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | inhibitor | 315661227 | ||
5168 | ENPP2 | ENZYME, DRUGGABLE GENOME, TRANSCRIPTION FACTOR BINDING | inhibitor | 336446947 | ZIRITAXESTAT |
Page: 1 |